Keyword: Abbott Laboratories
Abbott pledged to provide its neuromodulation tech for the public-private NIH research effort.
Abbott’s new, smarter version of its implantable monitor for detecting irregular heartbeats now reduces the rate of false detection by 97%.
The medtech giant said the data suggests adding the test to physicals of healthy middle-aged adults to help ward off the onset of heart disease.
Abbott Laboratories posted a 2% increase in sales for its first quarter this year, topping $7.5 billion worldwide and ahead of expectations.
The DOJ signed on to a whistleblower suit against one of Alere’s now-defunct subsidiaries over diabetic testing supplies and blood glucose readers.
Novo Nordisk started a new collaboration with Abbott and its Freestyle Libre line of digital health tools and continuous glucose monitoring devices.
Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a developer of mitral heart valve replacements.
Abbott received FDA approval for its Amplatzer Piccolo Occluder, which it describes as the world’s first implant for babies as little as two pounds.
After catapulting up five ranks on the list between 2016 and 2017, Abbott Laboratories will be looking to hold on to its third-place spot through 2024, on the laurels of its $25 billion acquisition of St. Jude Medical in January of last year.
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments.